SCHEMBL23749767

SCHEMBL23749767

CC(C)c1csc(=N)n1Cc1ccccc1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 4/20 0.44
SMN1; SMN2 Q16637 2/20 0.44
KDM4E B2RXH2 3/20 0.41
MAPT P10636 3/20 0.41
ALDH1A1 P00352 3/20 0.41
GAA P10253 2/20 0.41
GLA P06280 1/20 0.41
HPGD P15428 1/20 0.41
ALOX12 P18054 1/20 0.41
GSK3B P49841 5/20 0.41
GSK3A P49840 3/20 0.41
SLC5A2 P31639 2/20 0.38
CCNB2 O95067 1/20 0.38
CDK1 P06493 1/20 0.38
CCNB1 P14635 1/20 0.38
CCNB3 Q8WWL7 1/20 0.38
CYP19A1 P11511 1/20 0.38
NPSR1 Q6W5P4 3/20 0.37
MIF P14174 1/20 0.37
TSHR P16473 3/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23749756 0.79 SMN1; SMN2 (0.47) LMNASMN1; SMN2KDM4EMAPTALDH1A1
SCHEMBL23750073 0.77 SMN1; SMN2 (0.44) LMNASMN1; SMN2KDM4EMAPTALDH1A1
SCHEMBL25002134 0.73 POLB (0.46) LMNASMN1; SMN2KDM4EMAPTGSK3B
SCHEMBL23727301 0.73 RAB9A (0.42) LMNASMN1; SMN2KDM4EMAPTALDH1A1
SCHEMBL23727302 0.73 RAB9A (0.42) LMNASMN1; SMN2KDM4EMAPTALDH1A1
SCHEMBL23749771 0.72 LMNA (0.47) LMNASMN1; SMN2KDM4EMAPTALDH1A1
SCHEMBL23749867 0.71 LMNA (0.42) LMNASMN1; SMN2KDM4EMAPTALDH1A1
SCHEMBL23566136 0.63 PGR (0.41) LMNASMN1; SMN2KDM4EALDH1A1HPGD
SCHEMBL1170484 0.62 LMNA (1.00) LMNASMN1; SMN2KDM4EMAPTALDH1A1
SCHEMBL9161101 0.62 L3MBTL1 (0.65) LMNASMN1; SMN2KDM4EGAAGSK3B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230137893-A1 PYRROLO[2,3-b]PYRIDINE-3-CARBOXAMIDE COMPOSITIONS AND METHODS FOR AMELIORATING HEARING LOSS THE ROCKEFELLER UNIVERSITY (US) 2023-05-04 US disclosed
US-20230137893-A1 PYRROLO[2,3-b]PYRIDINE-3-CARBOXAMIDE COMPOSITIONS AND METHODS FOR AMELIORATING HEARING LOSS THE ROCKEFELLER UNIVERSITY (US) 2023-05-04 US disclosed
CN-115515579-A Pyrrolo [2,3-b ] pyridine-3-carboxamide compositions and methods for ameliorating hearing loss 洛克菲勒大学 2022-12-23 CN disclosed
WO-2021158936-A1 PYRROLO [2,3-B]PYRIDINE-3-CARBOXAMIDE COMPOSITIONS AND METHODS FOR AMELIORATING HEARING LOSS THE ROCKEFELLER UNIVERSITY (US) 2021-08-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230137893-A1 PYRROLO[2,3-b]PYRIDINE-3-CARBOXAMIDE COMPOSITIONS AND METHODS FOR AMELIORATING HEARING LOSS LATS2, LATS1, YAP1 LMNA 1731/4885SMN1; SMN2 2796/4885KDM4E 1083/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.